- Home
- GPCR vs EVT Comparison
GPCR vs EVT Comparison
Compare GPCR & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- EVT
- Stock Information
- Founded
- GPCR 2016
- EVT 2003
- Country
- GPCR United States
- EVT United States
- Employees
- GPCR N/A
- EVT N/A
- Industry
- GPCR
- EVT Finance Companies
- Sector
- GPCR
- EVT Finance
- Exchange
- GPCR Nasdaq
- EVT Nasdaq
- Market Cap
- GPCR 1.6B
- EVT 1.8B
- IPO Year
- GPCR 2023
- EVT N/A
- Fundamental
- Price
- GPCR $27.06
- EVT $24.41
- Analyst Decision
- GPCR Strong Buy
- EVT
- Analyst Count
- GPCR 7
- EVT 0
- Target Price
- GPCR $81.29
- EVT N/A
- AVG Volume (30 Days)
- GPCR 1.0M
- EVT 121.5K
- Earning Date
- GPCR 03-07-2025
- EVT 01-01-0001
- Dividend Yield
- GPCR N/A
- EVT 7.72%
- EPS Growth
- GPCR N/A
- EVT N/A
- EPS
- GPCR N/A
- EVT N/A
- Revenue
- GPCR N/A
- EVT N/A
- Revenue This Year
- GPCR N/A
- EVT N/A
- Revenue Next Year
- GPCR N/A
- EVT N/A
- P/E Ratio
- GPCR N/A
- EVT N/A
- Revenue Growth
- GPCR N/A
- EVT N/A
- 52 Week Low
- GPCR $23.50
- EVT $18.70
- 52 Week High
- GPCR $62.74
- EVT $23.82
- Technical
- Relative Strength Index (RSI)
- GPCR 42.52
- EVT 54.05
- Support Level
- GPCR $23.50
- EVT $23.63
- Resistance Level
- GPCR $27.68
- EVT $24.35
- Average True Range (ATR)
- GPCR 1.71
- EVT 0.29
- MACD
- GPCR 0.20
- EVT 0.07
- Stochastic Oscillator
- GPCR 51.30
- EVT 92.86
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.